Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: A LYSA study

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2919-2928

  Dubois, Sydney ^a   Viailly, Pierre Julien ^a,b   Mareschal, Sylvain ^a   Bohers, Elodie ^a   Bertrand, Philippe ^a   Ruminy, Philippe ^a   Maingonnat, Catherine ^a   Jais, Jean Philippe ^c   Peyrouze, Pauline ^d   Figeac, Martin ^d   Molina, Thierry J ^c   Desmots, Fabienne ^e   Fest, Thierry ^e   Haioun, Corinne ^f   Lamy, Thierry ^e   Copie Bergman, Christiane ^f   Brière, Josette ^g,h   Petrella, Tony ⁱ   Canioni, Danielle ^c   Fabiani, Bettina ^j   Coiffier, Bertrand ^k   Delarue, Richard ^c   Peyrade, Frédéric ^l   Bosly, André ^m   André, Marc ^m   Ketterer, Nicolas ⁿ   Salles, Gilles ^k   Tilly, Hervé ^a   Leroy, Karen ^f   Jardin, Fabrice ^a   more..

^a UNIVERSITY OF ROUEN   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIV LILLE   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSERM   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^j HÔPITAL SAINT ANTOINE   (France)

^k Univ Claude Bernard   (France)

^l Lacassagne Center   (France)

^m UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

ⁿ Children's Hospital Lausanne   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; STAT PROTEIN; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CELL RECEPTOR; CYCLOPHOSPHAMIDE; DNA BINDING PROTEIN; DOXORUBICIN; EXPORTIN 1 PROTEIN; GNA14 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE; KARYOPHERIN; MFHAS1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHOTRANSFERASE; PREDNISONE; R-CHOP PROTOCOL; TNFAIP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER PROGNOSIS; CONTROLLED STUDY; DNA MICROARRAY; EPIGENETICS; EXOME; GENE EXPRESSION PROFILING; GENE MUTATION; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOMATIC MUTATION; B LYMPHOCYTE; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; WHOLE EXOME SEQUENCING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELL CYCLE PROTEINS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; GENE EXPRESSION PROFILING; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KARYOPHERINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PRECISION MEDICINE; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3; VINCRISTINE; WHOLE EXOME SEQUENCING;

EID: 84975086212     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2305     Document Type: Article

References (52)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France IARC; 2008.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
3. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
4. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285-90.
5. Pfeifer M, Grau M, Lenze D, Wenzel S-S, Wolf A, Wollert-Wulf B, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013;110:12420-5.
6. Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
7. Lenz G, Staudt LM. Aggressive lymphomas. New Engl J Med 2010;362:1417-29.
8. Savage K, Monti S, Kutok J, Cattoretti G. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin. Blood 2003;102:3871-80.
9. Reichel J, Chadburn A, Rubinstein PG, Giulino-roth L, Tam W, Liu Y, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015;125:1061-73.
10. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-8.
11. Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M, Jais J-P, et al. Accurate classification of germinal center B-cell-like/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: A CALYM Study. J Mol Diagn 2015 Apr 9. [Epub ahead of print].
12. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J of Clin Oncol 2015;33:2848-56.
13. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-84.
14. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013;122:1256-65.
15. Mullighan CG. Genome sequencing of lymphoid malignancies. Blood 2013;122:3899-907.
16. Morin RD, Johnson Na, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
17. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
18. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
19. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
20. Zhang J, Grubor V. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci 2013;110:1398-403.
21. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118:2659-69.
22. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais J-P, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009;114:1236-42.
23. Khodabakhshi A, Morin R, Fejes A. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 2012;3:1308-19.
24. Bohers E, Mareschal S, Bertrand P, Viailly PJ, Dubois S, Maingonnat C, et al. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era. Leuk Lymphoma 2015;56:1213-22.
25. Mareschal S, Dubois S, Viailly P-J, Bertrand P, Bohers E, Maingonnat C, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2015;55:251-67.
26. Dubois S, Mareschal S, Picquenot J-M, Viailly P-J, Bohers E, Cornic M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy? Oncotarget 2015;6:16712-24.
27. Foundation for Statistical Computing. R: A language and environment for statistical computing. Vienna, Austria
28. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Med 2015;21:922-6.
29. Zheng X, Ding N, Song Y, Feng L, Zhu J. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int 2014;14:32.
30. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-53.
31. Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2014;53:144-53.
32. Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21:723-37.
33. Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J, et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 2012;107:491-500.
34. Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012;26:1383-90.
35. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu W -M, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood 2012;120:3986-97.
36. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-20.
37. Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 2015;29:1789-91.
38. Schmitz R, Hansmann M-L, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981-9.
39. Weniger MA, Melzner I, Menz CK, Wegener S, Bucura J, Dorsch K, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006;25:2679-84.
40. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New Engl J Med 2014;372:311-9.
41. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377-81.
42. Maréchal Y, Pesesse X, Jia Y, Pouillon V, Perez-Morga D, Daniel J, et al. Inositol 1, 3, 4, 5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. Proc Natl Acad Sci 2007;104:13978-83.
43. Tagawa H, Karnan S, Kasugai Y, Tuzuki S, Suzuki R, Hosokawa Y, et al. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8. Oncogene 2004;23:2576-81.
44. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28:108-17.
45. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012;120:4621-34.
46. Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, et al. Recurrent mutations of the Exportin 1 gene (XPO1) in primary mediastinal B-Cell Lymphoma: A Lysa Study. Blood 2015;126:129.
47. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011;96:1888-90.
48. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. New Engl J Med 2013;368:1408-16.
49. Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858-67.
50. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJM, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013;121:3666-74.
51. Fernández-Rodríguez C, Bellosillo B, García-García M, Sanchez-González B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia 2014;28:2104-6.
52. Bohers E, Viailly P-J, Dubois S, Bertrand P, Maingonnat C, Mareschal S, et al. Somatic mutations of cell-free circulating DNA detected by next generation sequencing reflect the genetic changes in both germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma tumors at the time of diagnosis. Haematologica 2011;96:1589-94.